Actinium Pharmaceuticals Announces Collaborative Research Partnership with Astellas Leveraging Actinium’s AWE Platform Technology Mar 28, 2018
Actinium Pharmaceuticals Announces Appointment of Jehan Rowlands, Pharm.D. as Vice-President, Head of Regulatory Affairs Mar 14, 2018
Actinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML Mar 13, 2018
Actinium Announces $15.4 Million in Expected Gross Proceeds from Recently Expired Rights Offering Mar 5, 2018
Actinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations Feb 28, 2018
Actinium Pharmaceuticals Announces Activation of Sixteenth Clinical Trial Site in the Pivotal Phase 3 SIERRA Trial for Iomab-B Feb 27, 2018
Actinium Pharmaceuticals Reiterates Previously Announced Expiration Date of March 2, 2018 at 5:00 PM ET and Amendment to Pricing Terms of its Rights Offering Feb 26, 2018
